ASCO 2023: Vorasidenib Delays Tumor Growth, Improves Survival in Patients With Grade 2 Glioma With IDH Mutation
Progression-free survival was significantly longer with vorasidenib versus placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.